ACER — Acer Therapeutics Share News
0.000.00%
Last trade - 00:00Brief: Acer Therapeutics Files Prospectus Related To Offer And Resale From Time To Time By The Selling Stockholders Of Up To 2.5 Million Shares Of Common Stock
U.S. STOCKS ON THE MOVE-SunPower, Snow Lake, Sea Ltd
U.S. STOCKS ON THE MOVE-Chinese ADRs, Star Equity, Starbucks
Acer Therapeutics rises on FDA's breakthrough therapy tag
Brief: Acer Therapeutics Regains Compliance With Nasdaq Listing Standard
Brief: Acer Therapeutics Enrolls First Patient In Its Phase 2A Clinical Trial Of Acer-801 For Treatment Of Moderate To Severe Vasomotor Symptoms Associated With Menopause
Acer Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Brief: Acer Therapeutics Posts Q4 Loss Per Share Of $0.31
Acer Therapeutics Inc expected to post a loss of 1cent a share - Earnings Preview
Brief: Acer Therapeutics Got Notice Of Delisting Or Failure To Satisfy Continued Listing Rule Or Standard From Nasdaq
Acer Therapeutics rises on FDA nod to start menopausal symptoms drug trial
Brief: Acer Therapeutics Announces ACER-801 IND Clearance For The Treatment Of Induced Vasomotor Symptoms
Brief: Acer Therapeutics Inc Files For Mixed Shelf Of Up To $100 Million - SEC Filing
Acer Therapeutics Inc reports results for the quarter ended in September - Earnings Summary
Brief: Acer Therapeutics Reports Q3 Loss Per Share $0.23
Brief: Acer Therapeutics And Relief Therapeutics Announce Issuance Of U.S. Patent 11,154,521 Covering ACER-001 Formulation
Brief: Relief Therapeutics And Acer Therapeutics Issue U.S. Patent 11,154,521 Covering ACER-001 Formulation
Brief: Acer Therapeutics Receives Notice Of Allowance Of Key U.S. Patent Application Covering Acer-001 Formulation
Brief: Acer Therapeutics And Relief Therapeutics Announce FDA Acceptance For NDA For Urea Cycle Disorders Treatment